Sandoz is positioning itself for long-term growth by making significant investments in its biosimilar capabilities over the coming years.
The Swiss generics and biosimilars giant sees a major commercial opportunity on the horizon as branded pharmaceutical companies face a wave of patent expirations.
This period, widely referred to in the industry as the patent cliff, is expected to open the door for biosimilar manufacturers to capture substantial market share.
Sandoz has described the coming years as a potential “golden decade” for the biosimilar sector, signalling strong confidence in its strategic direction.
Biosimilars are medicines that are highly similar to already-approved biological drugs, typically offering lower costs to healthcare systems and patients alike.
As blockbuster biologic treatments lose patent protection, companies like Sandoz are well placed to introduce competing products at more competitive price points.
The patent cliff has been a defining topic across the pharmaceutical industry, with billions of dollars worth of branded drug revenues set to become exposed to generic and biosimilar competition.
Sandoz has been building out its biosimilar pipeline and manufacturing capabilities in anticipation of this shift in the competitive landscape.
The company’s focus on biosimilars represents a deliberate move away from reliance on traditional small-molecule generics, which face intense pricing pressure and commoditisation.
Biosimilars, by contrast, require complex biological manufacturing processes that create higher barriers to entry and potentially stronger margins for established producers.
Sandoz’s ambitions in this space place it in direct competition with other major biosimilar developers globally, all of whom are targeting the same wave of expiring patents.
Healthcare systems across Europe and the United Kingdom have increasingly embraced biosimilars as a way to reduce spending without compromising on treatment quality.
The UK’s National Health Service has been among the more active adopters of biosimilar medicines, making it a potentially significant market for Sandoz’s growth plans.
With its dedicated biosimilar focus and stated confidence in the decade ahead, Sandoz appears intent on establishing itself as the dominant force in this rapidly expanding segment.